Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Maya Olaisen"'
Autor:
Reidar Fossmark, Maya Olaisen
Publikováno v:
Microorganisms, Vol 12, Iss 6, p 1110 (2024)
The use of proton pump inhibitors (PPIs) has increased considerably in many Western countries, and there is concern that numerous conditions and diseases associated with PPI use may be adverse events. The main function of gastric acid is to defend th
Externí odkaz:
https://doaj.org/article/2c572d91cdb247b9bf574b031d6a63a2
Autor:
Maya Olaisen, Mathias L. Richard, Vidar Beisvåg, Atle van Beelen Granlund, Elin S. Røyset, Olivier Rué, Tom Christian Martinsen, Arne Kristian Sandvik, Harry Sokol, Reidar Fossmark
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionFungal microbiota's involvement in the pathogenesis of Crohn's disease (CD) is incompletely understood. The terminal ileum is a predilection site both for primary involvement and recurrences of CD. We, therefore, assessed the mucosa-assoc
Externí odkaz:
https://doaj.org/article/fb4dfbf24965403ebd745d45ce5fb784
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment i
Externí odkaz:
https://doaj.org/article/470a6d32bafb411b8677c85e3c479b52
Autor:
Arne K. Sandvik, Maya Olaisen, Elin Synnøve Røyset, Reidar Fossmark, Arnar Flatberg, Atle van Beelen Granlund, Tom C. Martinsen
Publikováno v:
Inflammatory Bowel Diseases
Background Microbiota is most likely essential in the pathogenesis of Crohn’s disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majo
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology
Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment i
Autor:
Grethe Albrektsen, Maya Olaisen, Bodil Gilde, Atle van Beelen Granlund, Elin Synnøve Røyset, Arne K. Sandvik, Arnar Flatberg, Olav Spigset, Reidar Fossmark, Wenche Rødseth Brede, Tom C. Martinsen
Publikováno v:
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology and Therapeutics
Alimentary Pharmacology and Therapeutics
Background 5‐aminosalicylic acid (5‐ASA) is the first‐line therapy for ulcerative colitis (UC). 5‐ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N‐acetyltransferase (NAT). Large variations in m
Autor:
Maya Olaisen, Reidar Fossmark
Publikováno v:
Inflammatory Bowel Diseases. 28:e121-e121
Publikováno v:
Journal of Crohn's and Colitis. 14:S605-S606
Background Oral mesalazine is the mainstay treatment of ulcerative colitis (UC). Mesalazine exerts its anti-inflammatory effect locally in the colonic mucosa. The mucosal mesalazine concentration is inversely correlated with the degree of inflammatio
Autor:
T. C. Martinsen, W R Brede, Elin Synnøve Røyset, Olav Spigset, Maya Olaisen, B Granlund, Arne K. Sandvik, Reidar Fossmark, Arnar Flatberg
Publikováno v:
Journal of Crohn's and Colitis. 13:S538-S539
Autor:
Maya Olaisen, Reidar Fossmark
Publikováno v:
Alimentary Pharmacology & Therapeutics. 49:1532-1532